According to the proposed A/T/N framework [2,3], AD is defined by the presence of pathology within the following biomarker categories: intracellularly aggregated amyloid-beta (Aβ; “A”), extracellularly aggregated pathological tau (“T”), and neurodegeneration or neuronal injury (“N”). The gene discussed is MAPT; the disease is Alzheimer disease.